United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma.

Item

http://www.wikidata.org/entity/Q52841629

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

United Kingdom Myeloma Forum ( ...... se of bendamustine in myeloma.

@en

United Kingdom Myeloma Forum

@nl

type

Item

label

United Kingdom Myeloma Forum ( ...... se of bendamustine in myeloma.

@en

United Kingdom Myeloma Forum

@nl

prefLabel

United Kingdom Myeloma Forum ( ...... se of bendamustine in myeloma.

@en

United Kingdom Myeloma Forum

@nl

P1476

United Kingdom Myeloma Forum ( ...... use of bendamustine in myeloma

@en

P2093

F Davies

http://www.w3.org/2001/XMLSchema#string

G Cook

http://www.w3.org/2001/XMLSchema#string

G Pratt

http://www.w3.org/2001/XMLSchema#string

J A Snowden

http://www.w3.org/2001/XMLSchema#string

J Bird

http://www.w3.org/2001/XMLSchema#string

J Cavenagh

http://www.w3.org/2001/XMLSchema#string

K Yong

http://www.w3.org/2001/XMLSchema#string

M Lai

http://www.w3.org/2001/XMLSchema#string

R Owen

http://www.w3.org/2001/XMLSchema#string

S Bell

http://www.w3.org/2001/XMLSchema#string

P2860

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.

Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

P304

20-28

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IJLH.12097

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gareth J Morgan

P577

2013-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236327671

http://www.w3.org/2001/XMLSchema#string

P698

23615178

http://www.w3.org/2001/XMLSchema#string